Summary The cytotoxicity of three platinum complexes, cis-diamminedichloroplatinum(II) (cis-platin), cisdichloro-trans-dihydroxy-cis-bis (isopropylamine) platinum(IV), (CHIP) and diammine (1, 1-cyclobutanedicarboxylato) platinum(II) (carboplatin) on Chinese Hamster ovary (CHO) and mouse sarcoma RIF-l cells cultured in vitro has been compared.
Summary The cytotoxicity of three platinum complexes, cis-diamminedichloroplatinum(II) (cis-platin), cisdichloro-trans-dihydroxy-cis-bis (isopropylamine) platinum(IV), (CHIP) and diammine (1, 1-cyclobutanedicarboxylato) platinum(II) (carboplatin) on Chinese Hamster ovary (CHO) and mouse sarcoma RIF-l cells cultured in vitro has been compared.
The tumour cell line was much more sensitive to the cytotoxic action of the three agents compared to the CHO cell line. CHIP and carboplatin gave similar dose-response curves, both being much less toxic than cis-platin.
The effect of thiol modification on platinum toxicity was also investigated. Substantial reduction in the intracellular non-protein sulphydryl content markedly enhanced the cytotoxicity of CHIP but had much less effect on carboplatin and cis-platin. Thiol depletion by diethylmaleate had a negligible effect on cis-platin toxicity.
Cis-platin is an effective anti-tumour agent and is well established in the clinic (Gottlieb & Drewinko, 1975; Yagoda et al., 1976; Young et al., 1976) , but has dose-limiting nephrotoxicity (Krakoff, 1979) . In order to combat the side effects of cis-platin, second generation platinum complexes have been developed with much less toxicity to normal tissue (Harrap et al., 1980) . Two such compounds, CHIP and carboplatin, have emerged for clinical studies. CHIP has reached phase II clinical trials (Wong et al., 1985) , and carboplatin, phase III clinical trials (Canetta et al., 1985) .
Manipulation of intracellular thiols may be useful clinically in either enhancing drug toxicity to the tumour or by protecting against normal tissue damage to increase the therapeutic gain. There are numerous reports that thiols can protect animals and cells against the toxicity of alkylating agents (Connors et al., 1964; Connors, 1966; Contractor, 1963; Walker & Smith, 1969) .
Glutathione (GSH) is the major intracellular non-protein sulphydryl (NPSH) in living cells and is generally accepted to play a mechanistic role in cancer treatment (Arrick & Nathan, 1984) , the remaining component of NPSH is comprised of cysteine, y-glutamylcysteine, lipoic acid and coenzyme A. GSH can interact with a variety of anti-neoplastic drugs, mainly through nucleophilic thioether formation or oxidation-reduction reactions. To examine the effect of thiol depletion on platinum sensitivity we have used diethylmaleate (DEM) or DL-buthionine-SR-sulphoximine (BSO) prior to platinum treatment. BSO is a specific inhibitor of glutathione biosynthesis (Griffith & Meister, 1979) and over 90% reduction in glutathione levels can be achieved in cell culture. DEM, on the other hand, is less specific and reacts with non-protein thiols to form a stable adduct (Bump et al., 1982 DEM (Sigma Chem. Co.) was initially diluted in absolute alcohol at 100mM and subsequently diluted in saline.
NPSH determination Ice-cold trichloroacetic acid was used to precipitate protein and the supernatant was assayed spectrophotometrically for NPSH using Ellmans reagent (1959) . NPSH was measured in control CHO and RIF-1 cells and also after 1 hour's treatment at 37°C with a platinum dose sufficient to reduce cell survival to 10%.
GSH determination
This was assayed spectrophotometrically by the procedure developed by Tietze (1969 shoulders of the RIF survival curves were almost absent with CHIP and carboplatin and completely absent with cis-platin.
Effect of thiol depletion on platinum toxicity Monolayers of CHO cells were treated with 0.2mM DEM for 2 h at 37°C prior to platinum exposure for a further 1 h at 37°C. Under these conditions the NPSH content of CHO cells was reduced to a level such that it was no longer detectable. DEM pretreatment did not alter the cellular response to cis-platin (Figure 4 ) and potentiated carboplatin 
Intracellular thiol levels
The GSH and NPSH contents of CHO and RIF-1 cells are shown in Table I . The levels were not significantly altered after platinum treatment.
Discussion
Carboplatin and CHIP are much less toxic in vitro on both the normal and tumour cell lines, when compared with the parent compound, cis-platin. In agreement with Ohnuma et al. (1986) we found no effect of cell density on the cytotoxicity of cis-platin or carboplatin. However, we did find CHIP response varied significantly with cell density, i.e. CHIP became more cytotoxic with a decrease in cell density (data not shown). Despite the fact that CHIP and carboplatin are quite different in chemical structure, they exhibit similar dose-response curves. The absence of the shoulder on the RIF survival response may indicate that the tumour line is less able or unable to repair sub-lethal damage induced by platinum complexes. The greater sensitivity of RIF-1 cells to platinum agents compared to CHO cells could be due to differences in drug uptake (Eichlotz-Wirth & Hietel, 1986) , increased binding of platinum to DNA in the sensitive line (Roberts & Fraval, 1978) or the ability to excise platinum adducts from DNA (Fraval & Roberts, 1979) . Cis-platin (Roberts & Fravel, 1978) and CHIP (Edwards & Nias, 1986) have both been shown to be preferentially cytotoxic towards cells-in the G1 phase of the-cell 'cycle and therefore cell lines with longer G1 phases may be more sensitive to platinum treatment than cells with shorter G1 times. This agrees with the cell cycle time of 24 hours in the RIF-I compared to 13-14 hours in the CHO cells assuming cells with longer cell cycles have longer G1 phases. Other workers have looked at the effect of platinum toxicity on sensitive and resistant human carcinoma cell lines in vitro in relation to the intracellular glutathione content, and found in some instances that resistance to platinum agents correlated with higher levels of glutathione (Wolf et al., 1985; Hamilton et al., 1985; Behrens et al., 1985) . However, Andrews et al. (1985) showed that their platinum resistant line had the same glutathione content as the sensitive cell line. Our Of the three platinum drugs only CHIP was substantially affected by thiol depletion in CHO cells (ER= 2.4). A similar result was also confirmed with the RIF-1 cells. Recent data using synchronised CHO cells have shown that the cell cycle dependence of CHIP is removed if the cells are pretreated with BSO (Edwards, 1986) . The higher oxidation state of CHIP compared to cis-platin and carboplatin may be a contributory factor in its modification by thiols. It has been proposed that CHIP requires intracellular reduction to a Pt II complex for activity (Blatter et al., 1984) , also that CHIP can be reduced by oxidised DNA (Butler et al., 1985) . However, both these processes are less likely to occur in thiol depleted cells. To add further controversy Andrews et al. (1985) found no effect on CHIP toxicity in human ovarian carcinoma cells which had been previously treated with BSO. The carcinoma cell line was 10 times more sensitive to cis-platin than RIF-l cells and therefore potentiation of CHIP by BSO might depend on the inherent sensitivity of the cell line to CHIP such that extremely sensitive cell lines may not be made more sensitive to CHIP by thiol depletion.
It has been shown that thiourea can reverse Pt(II) induced DNA cross-links and lethal lesions in isolated DNA , and that thiourea can protect cells against the toxicity of platinum II complexes (Zwelling et al., 1979) . We have also shown that thiourea can protect against the toxicity of cis-platin, CHIP and carboplatin (unpublished data). Naturally occurring thiols inside the cell may also be able to protect against platinum toxicity in a similar fashion to thiourea but to a lesser degree. Thus reduction of intracellular glutathione located near Pt-DNA adducts may be responsible for enhanced platinum toxicity.
In conclusion. RIF-1 cells did not differ appreciably in their GSH or NPSH content from CHO cells and yet they are much more sensitive to platinum toxicity. The concentration of NPSH in specific cell organelles may be more important than the total cellular NPSH with regard to platinum toxicity. Cellular sensitivity to Pt IV complexes can be increased significantly in thiol depleted cells. Thiol. depletion has little effect on Pt II complexes. As with all chemotherapeutic drugs, effective therapy is marred by doselimiting toxicities and the emergence of drug resistance by the tumour. The use of biochemical modifiers that can either sensitize tumour cells, or minimise drug resistance, may improve the efficacy of platinating agents. BSO is a relatively non-toxic compound and its use in combined modality treatments may be of some clinical benefit. This work was supported by a grant from the Cancer Research Campaign.
